vs
Side-by-side financial comparison of Amylyx Pharmaceuticals, Inc. (AMLX) and Keros Therapeutics, Inc. (KROS). Click either name above to swap in a different company.
Keros Therapeutics, Inc. produced more free cash flow last quarter ($106.0M vs $-28.0M). Over the past eight quarters, Keros Therapeutics, Inc.'s revenue compounded faster (593.7% CAGR vs -100.0%).
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for hematological disorders, musculoskeletal diseases and anemia, serving underserved patient groups with unmet medical needs from its core U.S. base.
AMLX vs KROS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $0 | $385.0K |
| Net Profit | $-33.0M | — |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | — | -87.3% |
| Net Profit YoY | 12.1% | 49.0% |
| EPS (diluted) | $-0.28 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $0 | $385.0K | ||
| Q3 25 | $0 | $14.3M | ||
| Q2 25 | $0 | $18.2M | ||
| Q1 25 | $0 | $211.2M | ||
| Q4 24 | $-665.0K | — | ||
| Q3 24 | $416.0K | $388.0K | ||
| Q2 24 | $-1.0M | $37.0K | ||
| Q1 24 | $88.6M | $83.0K |
| Q4 25 | $-33.0M | — | ||
| Q3 25 | $-34.4M | $-7.3M | ||
| Q2 25 | $-41.4M | $-30.7M | ||
| Q1 25 | $-35.9M | $148.5M | ||
| Q4 24 | $-37.5M | — | ||
| Q3 24 | $-72.7M | $-53.0M | ||
| Q2 24 | $-72.7M | $-45.3M | ||
| Q1 24 | $-118.8M | $-43.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 100.8% | — | ||
| Q1 24 | 93.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -107.9% | ||
| Q2 25 | — | -219.2% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | 6113.4% | — | ||
| Q3 24 | -18187.7% | -15117.8% | ||
| Q2 24 | 7457.1% | -136321.6% | ||
| Q1 24 | -137.8% | -58413.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | -51.0% | ||
| Q2 25 | — | -169.0% | ||
| Q1 25 | — | 70.3% | ||
| Q4 24 | 5646.0% | — | ||
| Q3 24 | -17476.9% | -13648.5% | ||
| Q2 24 | 7106.5% | -122316.2% | ||
| Q1 24 | -134.0% | -51944.6% |
| Q4 25 | $-0.28 | — | ||
| Q3 25 | $-0.37 | $-0.18 | ||
| Q2 25 | $-0.46 | $-0.76 | ||
| Q1 25 | $-0.42 | $3.62 | ||
| Q4 24 | $-0.54 | — | ||
| Q3 24 | $-1.07 | $-1.41 | ||
| Q2 24 | $-1.07 | $-1.25 | ||
| Q1 24 | $-1.75 | $-1.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $317.0M | $287.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $305.3M | $303.1M |
| Total Assets | $332.6M | $338.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $317.0M | $287.4M | ||
| Q3 25 | $344.0M | $693.5M | ||
| Q2 25 | $180.8M | $690.2M | ||
| Q1 25 | $204.1M | $720.5M | ||
| Q4 24 | $176.5M | — | ||
| Q3 24 | $234.4M | $530.7M | ||
| Q2 24 | $309.8M | $405.9M | ||
| Q1 24 | $373.3M | $442.4M |
| Q4 25 | $305.3M | $303.1M | ||
| Q3 25 | $332.0M | $703.6M | ||
| Q2 25 | $167.9M | $706.7M | ||
| Q1 25 | $201.4M | $728.9M | ||
| Q4 24 | $164.8M | — | ||
| Q3 24 | $196.2M | $532.8M | ||
| Q2 24 | $261.3M | $420.9M | ||
| Q1 24 | $324.4M | $453.9M |
| Q4 25 | $332.6M | $338.0M | ||
| Q3 25 | $362.7M | $742.8M | ||
| Q2 25 | $194.6M | $757.2M | ||
| Q1 25 | $219.7M | $784.6M | ||
| Q4 24 | $193.6M | — | ||
| Q3 24 | $250.7M | $579.3M | ||
| Q2 24 | $332.2M | $455.0M | ||
| Q1 24 | $417.5M | $485.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-27.9M | $107.5M |
| Free Cash FlowOCF − Capex | $-28.0M | $106.0M |
| FCF MarginFCF / Revenue | — | 27520.5% |
| Capex IntensityCapex / Revenue | — | 402.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-123.5M | $239.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-27.9M | $107.5M | ||
| Q3 25 | $-30.4M | $3.2M | ||
| Q2 25 | $-25.2M | $-29.6M | ||
| Q1 25 | $-39.8M | $161.2M | ||
| Q4 24 | $-59.0M | — | ||
| Q3 24 | $-41.6M | $-30.5M | ||
| Q2 24 | $-66.6M | $-39.8M | ||
| Q1 24 | $-489.0K | $-44.6M |
| Q4 25 | $-28.0M | $106.0M | ||
| Q3 25 | $-30.4M | $3.1M | ||
| Q2 25 | $-25.3M | $-30.3M | ||
| Q1 25 | $-39.8M | $160.6M | ||
| Q4 24 | $-59.0M | — | ||
| Q3 24 | $-41.6M | $-30.9M | ||
| Q2 24 | $-66.7M | $-40.1M | ||
| Q1 24 | $-556.0K | $-45.5M |
| Q4 25 | — | 27520.5% | ||
| Q3 25 | — | 21.9% | ||
| Q2 25 | — | -167.0% | ||
| Q1 25 | — | 76.0% | ||
| Q4 24 | 8876.4% | — | ||
| Q3 24 | -9997.4% | -7960.3% | ||
| Q2 24 | 6517.0% | -108408.1% | ||
| Q1 24 | -0.6% | -54826.5% |
| Q4 25 | — | 402.9% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | -3.0% | — | ||
| Q3 24 | 4.6% | 99.5% | ||
| Q2 24 | -8.7% | 837.8% | ||
| Q1 24 | 0.1% | 1139.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.09× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
